آنتی­ بادی MITF (Microphthalmia-Associated Transcription Factor) (C5+D5)

Name: MITF (Microphthalmia-Associated Transcription Factor) Antibody Clone C5+D5

Description and applications: This antibody reacts with human microphthalmia transcription factor (MITF). The MITF gene (microphthalmia transcription factor, MITF) encodes a nuclear helix-loop-helix transcription factor involved in pigmentation and mast and bone cell development. The MITF gene is essential for the normal development of melanocytes and is responsible for the regulation of the expression of other genes related to the melanocytic lineage: tyrosinase genes, SILV/PMEL17/GP100 (encoding HMB45), MLANA/MART1 (coding for Melan A), TRP-1, and TRP-2. Mutation of the MITF gene in humans causes Waardenburg syndrome IIA and Tietz syndrome, characterized by pigmentation disorders and deafness, the latter due to melanocyte deficiency in the inner ear. There are two known isoforms of MITF that differ in 66 amino acid residues from the amino terminus. The shortest isoform of MITF is melanocyte-specific. MITF-M is expressed in both normal and malignant melanocytes. The other isoforms, MITF-A, MITF-C, and MITF-H, differ structurally from MITF-M at the amino terminus and are expressed in osteoclasts, mast and heart cells, and in B16 melanoma cell lines (although not in other melanoma cell lines). The anti-MITF antibody reacts against the melanocytic and non melanocytic isoforms of the MITF gene, and although it does not distinguish between benign and malignant melanocytic lesions, it shows high sensitivity and specificity as a histopathological marker of melanocytes and melanocyte-derived neoplasms (melanomas). Using MITF and Melan A in the same panel of melanoma markers, the sensitivity (95%) and specificity (100%) values obtained are higher than those obtained using the S100 protein and HMB45, even in cytological samples. MITF, Melan-A, and tyrosinase are sensitive markers for the diagnosis of epithelioid melanomas. Low levels of Melan-A and MITF have been shown to correlate with a poorer prognosis. MITF has demonstrated 100% sensitivity and specificity to detect invasive malignancies of melanocytic origin and to study sentinel lymph nodes.

Composition: Anti-human MITF mouse monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide.